<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLINDAMAX LOTION- clindamycin phosphate suspension </strong><br>PharmaDerm, A division of Nycomed US Inc.<br></p></div>
<h1>ClindaMax<span class="Sup">®</span> Lotion <br>(clindamycin phosphate topical suspension USP 1%)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p><span class="Bold">FOR EXTERNAL USE ONLY</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">ClindaMax<span class="Sup">®</span> Lotion (clindamycin phosphate topical suspension USP 1%) contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter.
</p>
<p>Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.
</p>
<p>The topical lotion contains cetostearyl alcohol (2.5%), glycerin, glyceryl stearate SE (with potassium monostearate), isostearyl alcohol (2.5%), methylparaben (0.3%), sodium lauroyl sarcosinate, stearic acid and purified water.
</p>
<p>The structural formula is represented below:
</p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64c28c73-5a2a-4bb0-bcec-9948463a9c8f&amp;name=clindamax-lotion-01.jpg">
</div>
<p>The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-<span class="Italics">trans</span>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<span class="Italics">threo</span>-α–D-<span class="Italics">galacto</span>-octopyranoside 2-(dihydrogen phosphate).
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Although clindamycin phosphate is inactive <span class="Italics">in vitro</span>, rapid <span class="Italics">in vivo</span> hydrolysis converts this compound to the antibacterially active clindamycin.<br>         Cross resistance has been demonstrated between clindamycin and lincomycin.<br>         Antagonism has been demonstrated between clindamycin and erythromycin.<br>         Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0-3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.
</p>
<p>Clindamycin activity has been demonstrated in comedones from <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients. The mean concentration of antibiotic activity in extracted comedones after application of Clindamycin Phosphate Topical Solution for 4 weeks was 597 mcg/g of comedonal material (range 0-1490). Clindamycin <span class="Italics">in vitro</span> inhibits all <span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span> cultures tested (MICs 0.4 mcg/mL). Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">ClindaMax<span class="Sup">®</span> Lotion (clindamycin phosphate topical suspension USP 1%) is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span>. In view of the potential for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, the physician should consider whether other agents are more appropriate. (See <span class="Bold"><a href="#s5">CONTRAINDICATIONS,</a><a href="#s6">WARNINGS</a></span> and <span class="Bold"><a href="#s13">ADVERSE REACTIONS</a></span>.)
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">ClindaMax<span class="Sup">®</span> Lotion (clindamycin phosphate topical suspension USP 1%) is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to preparations containing clindamycin or lincomycin, a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> or <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or a history of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First"><span class="Bold">Orally and parenterally administered clindamycin has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which may result in patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of topical and systemic clindamycin.</span></p>
<p><span class="Bold">Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. The <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> is usually characterized by severe persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and may be associated with the passage of blood and mucus. Endoscopic examination may reveal <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>.</span><span class="Bold Underline">Stool culture for</span><span class="Bold Italics Underline">Clostridium difficile</span><span class="Bold Underline">and stool assay for</span><span class="Bold Italics Underline">C. difficile</span><span class="Bold Underline">toxin may be helpful diagnostically.</span></p>
<p><span class="Bold">When significant <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</span></p>
<p><span class="Bold">Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> produced by</span><span class="Bold Italics">Clostridium difficile</span><span class="Bold">. The usual adult dosage is 500 mg to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days.</span> <span class="Bold Underline"> Cholestyramine or colestipol resins bind vancomycin</span><span class="Bold Italics Underline">in vitro</span><span class="Bold">. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s8"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General</span> - ClindaMax<span class="Sup">®</span> Lotion (clindamycin phosphate topical suspension USP 1%) should be prescribed with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> individuals.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s9"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s10"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:</span><span class="Underline">Teratogenic Effects:</span><span class="Italics">Pregnancy Category B</span>: Reproduction studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin ranging from 100 to 600 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to clindamycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s11"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether clindamycin is excreted in human milk following use of Clindamycin Phosphate. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s12"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use</span>: Safety and effectiveness in pediatric patients under the age of 12 have not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s13"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">In 18 clinical studies of various formulations of topical clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].
</p>
<a name="t300"></a><table width="100%">
<caption><span>Number of Patients Reporting Events
</span></caption>
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<col align="left" width="25.000%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote"># not recorded
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">* of 126 subjects
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Bold">Treatment Emergent </span></td>
<td align="center" valign="top"><span class="Bold">Solution</span></td>
<td align="center" valign="top"><span class="Bold">Gel</span></td>
<td align="center" valign="top"><span class="Bold">Lotion</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">Adverse Event<br><br></span></td>
<td align="center" valign="top"><span class="Bold">n= 553 (%)</span></td>
<td align="center" valign="top"><span class="Bold">n= 148 (%)</span></td>
<td align="center" valign="top"><span class="Bold">n= 160 (%)</span></td>
</tr>
<tr>
<td align="left" valign="top">Burning
</td>
<td align="center" valign="top">  62 (11)
</td>
<td align="center" valign="top">15 (10)
</td>
<td align="center" valign="top">17 (11)
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span>
</td>
<td align="center" valign="top">   36 (7)
</td>
<td align="center" valign="top">15 (10)
</td>
<td align="center" valign="top">17 (11)
</td>
</tr>
<tr>
<td align="left" valign="top">Burning/<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span>
</td>
<td align="center" valign="top"> 60 (11)
</td>
<td align="center" valign="top"> # ( - )
</td>
<td align="center" valign="top"> # ( - )
</td>
</tr>
<tr>
<td align="left" valign="top">Dryness
</td>
<td align="center" valign="top">105 (19)
</td>
<td align="center" valign="top">34 (23)
</td>
<td align="center" valign="top">29 (18)
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>
</td>
<td align="center" valign="top"> 86 (16)
</td>
<td align="center" valign="top"> 10 (7)
</td>
<td align="center" valign="top">22 (14)
</td>
</tr>
<tr>
<td align="left" valign="top">Oiliness/<span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">Oily Skin</span>
</td>
<td align="center" valign="top">    8 (1)
</td>
<td align="center" valign="top">26 (18)
</td>
<td align="center" valign="top">12*(10)
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Peeling</span>
</td>
<td align="center" valign="top"> 61 (11)
</td>
<td align="center" valign="top"> # ( - )
</td>
<td align="center" valign="top"> 11 (7)
</td>
</tr>
</tbody>
</table>
<p>Orally and parenterally administered clindamycin has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which may end fatally.
</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see <span class="Bold"><a href="#s6">WARNINGS</a></span>).
</p>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> as well as gram-negative <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span> have also been reported in association with the use of topical formulations of clindamycin.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s14"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Topically applied ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) can be absorbed in sufficient amounts to produce systemic effects. (See <span class="Bold"><a href="#s6">WARNINGS</a></span>.)
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s15"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Apply a thin film of ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) twice daily to affected area.
</p>
<p>Shake well immediately before using.
</p>
<p>Keep in container and keep tightly closed.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s16"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">ClindaMax® Lotion (clindamycin phosphate topical suspension USP 1%) containing clindamycin phosphate equivalent to 10 mg clindamycin per mL, is supplied as follows:
</p>
<dl class="Disc">
<dt> 
</dt>
<dd>NDC 0462-0391-60  60 mL bottle
</dd>
</dl>
<p>Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature].
</p>
<p>PharmaDerm®
							<br>
							A division of Nycomed US Inc., Melville, NY 11747<br>www.pharmaderm.com
</p>
<p>I8391C/IF8391C<br>#43<br>R10/08
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s101"></a><a name="section-12"></a><p></p>
<h1>
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 mL BOTTLE LABEL
</h1>
<p class="First"><span class="Bold">
PharmaDerm®
</span></p>
<p><span class="Bold">
NDC 0462-0391-60
</span></p>
<p><span class="Bold">
ClindaMax® Lotion
</span></p>
<p><span class="Bold">
(clindamycin phosphate
</span></p>
<p><span class="Bold">
topical suspension
</span></p>
<p><span class="Bold">
USP 1%)
</span></p>
<p><span class="Bold">
equivalent to 1%
</span></p>
<p><span class="Bold">
(10 mg/mL) clindamycin
</span></p>
<p><span class="Bold">
FOR TOPICAL
</span></p>
<p><span class="Bold">
USE ONLY
</span></p>
<p><span class="Bold">
Rx only
</span></p>
<p><span class="Bold">
60 mL
</span></p>
<div class="Figure">
<a name="f01"></a><img alt="Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64c28c73-5a2a-4bb0-bcec-9948463a9c8f&amp;name=clindamax-lotion-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s102"></a><a name="section-13"></a><p></p>
<h1>
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 60 mL CARTON
</h1>
<p class="First"><span class="Bold">
PharmaDerm®
</span></p>
<p><span class="Bold">
NDC 0462-0391-60
</span></p>
<p><span class="Bold">
ClindaMax® Lotion
</span></p>
<p><span class="Bold">
(clindamycin phosphate
</span></p>
<p><span class="Bold">
topical suspension
</span></p>
<p><span class="Bold">
USP 1%)
</span></p>
<p><span class="Bold">
equivalent to 1%
</span></p>
<p><span class="Bold">
(10 mg/mL) clindamycin
</span></p>
<p><span class="Bold">
FOR TOPICAL
</span></p>
<p><span class="Bold">
USE ONLY
</span></p>
<p><span class="Bold">
Rx only
</span></p>
<p><span class="Bold">
60 mL
</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=64c28c73-5a2a-4bb0-bcec-9948463a9c8f&amp;name=clindamax-lotion-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLINDAMAX LOTION 		
					</strong><br><span class="contentTableReg">clindamycin phosphate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0462-0391</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>clindamycin phosphate</strong> (clindamycin) </td>
<td class="formItem">clindamycin phosphate</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cetostearyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>glyceryl monostearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0462-0391-60</td>
<td class="formItem">60 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065067</td>
<td class="formItem">01/31/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PharmaDerm, A division of Nycomed US Inc.
							(043838424)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Nycomed US Inc. (043838424)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nycomed US Inc.</td>
<td class="formItem"></td>
<td class="formItem">043838424</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nycomed US Inc.</td>
<td class="formItem"></td>
<td class="formItem">174491316</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0ebfdc10-471e-41d8-9396-b1e2a0760b7e</div>
<div>Set id: 64c28c73-5a2a-4bb0-bcec-9948463a9c8f</div>
<div>Version: 2</div>
<div>Effective Time: 20090815</div>
</div>
</div> <div class="DistributorName">PharmaDerm, A division of Nycomed US Inc.</div></p>
</body></html>
